Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	451.36	182.95	17.45	25.82	57.03
Revenue Growth (YoY)	146.71%	948.62%	-32.42%	-54.73%	-
Cost of Revenue	30.68	12.83	1.59	0.96	2.08
Gross Profit	420.68	170.13	15.85	24.86	54.95
Selling, General & Admin	427.32	237.31	108.7	44.95	25.4
Research & Development	64.32	53.39	50.31	42.62	41.71
Total Operating Expenses	491.65	290.7	159.01	87.57	67.11
Operating Income	-70.97	-120.57	-143.16	-62.71	-12.16
Interest Income	15.75	15.01	10.34	3.5	0.04
Interest Expense	-8.94	-7.85	-3.35	-2.2	-
Other Non-Operating Income (Expense)	-0.2	1.94	0.27	0.77	1.58
Total Non-Operating Income (Expense)	6.61	9.11	7.27	2.07	1.61
Pretax Income	-64.36	-111.46	-135.89	-60.64	-10.54
Provision for Income Taxes	-2.06	-	-	0	-0.06
Net Income	-66.42	-115.55	-135.89	-62.09	-13.83
Net Income to Common	-66.42	-115.55	-135.89	-62.09	-13.83
Shares Outstanding (Basic)	42	38	29	25	21
Shares Outstanding (Diluted)	42	38	29	25	21
Shares Change (YoY)	11.11%	27.98%	19.35%	19.78%	231.12%
EPS (Basic)	-1.59	-3.07	-4.62	-2.52	-0.67
EPS (Diluted)	-1.59	-3.07	-4.62	-2.52	-0.67
Free Cash Flow	-22.31	-84.59	-119	-49.54	3.16
Free Cash Flow Per Share	-0.53	-2.25	-4.05	-2.01	0.15
Gross Margin	93.20%	92.99%	90.87%	96.30%	96.36%
Operating Margin	-15.72%	-65.90%	-820.53%	-242.92%	-21.32%
Profit Margin	-14.72%	-63.16%	-778.89%	-240.51%	-24.25%
FCF Margin	-4.94%	-46.24%	-682.04%	-191.88%	5.54%
EBITDA	-69.15	-119.34	-142.28	-62.39	-11.85
EBITDA Margin	-15.32%	-65.23%	-815.50%	-241.66%	-20.77%
EBIT	-70.97	-120.57	-143.16	-62.71	-12.16
EBIT Margin	-15.72%	-65.90%	-820.53%	-242.92%	-21.32%
Effective Tax Rate	3.20%	0.00%	0.00%	-0.01%	0.52%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q